GET DAILY SIGNALSWhy Is iRhythm Holdings (IRTC) Stock Down -28.64% Today?
Key Takeaways
- IRTC shares plunged roughly 28.6% in Thursday trading, falling about $37 to near $93 after closing the prior session at $130.19.
- The selloff was driven by third-quarter earnings that revealed a sharp deceleration in revenue growth and softness in the Zio AT telemetry business.
- Management pushed its next-generation Zio MCT submission to the FDA from 2026 into 2027, a timeline slip that pressured sentiment.
- The full-year guidance raise was largely carried by newly acquired VitalConnect revenue, implying only modest organic growth near term.
- Traders are now watching Zio AT demand trends, the VitalConnect integration, and any further analyst estimate revisions.
- For deeper insight into this name, explore its Price Targets, Earnings, and Forecast pages.
- For AI-driven trading ideas across the market, visit Trending AI Robots.
Opening Summary
iRhythm Holdings, Inc. (IRTC), a digital-healthcare and medical-technology company best known for its Zio wearable cardiac-monitoring patches, saw its stock suffer one of its sharpest single-day declines on record Thursday. After closing the previous session at $130.19, shares tumbled to roughly $92.91 in intraday trading, a drop of approximately 28.6%. The move was an earnings-driven selloff: investors zeroed in on decelerating top-line growth and a weakening telemetry segment even as the company delivered a sizable profitability beat.
Q3 Earnings: A Margin Beat Overshadowed by Slowing Growth
The immediate catalyst was the company's third-quarter 2026 report, released after the bell on November 5. Revenue rose 14.9% year over year to $221.6 million, roughly in line with the $222.3 million consensus but marking the first quarter in more than a year in which growth fell below 20%. Adjusted earnings per share of $0.82 crushed the roughly $0.05 consensus, and adjusted EBITDA of $51.2 million produced a record 23.1% margin. Yet the market focused squarely on the growth narrative: seven straight quarters of 20%-plus expansion had come to an end, and the top line was no longer compounding at the rate investors had priced in.
Zio AT Softness and the Zio MCT Delay
Beneath the headline numbers, two product-level developments rattled shareholders. First, revenue from Zio AT, the company's mobile cardiac telemetry offering, was roughly flat year over year after growing more than 50% in 2025. Management attributed the stall to new accounts deferring onboarding while they await the integration of VitalConnect, which IRTC acquired on October 5. Executives warned the drag could persist for one to two quarters and guided Zio AT revenue down about 10% in the fourth quarter.
Second, the company disclosed that it no longer plans to submit its internally developed next-generation Zio MCT device to the FDA in 2026, instead pushing the filing into 2027 as resources shift toward integrating VitalConnect. Because a first-half 2027 launch had been reaffirmed on prior calls, the delay was read as a meaningful setback to the product roadmap.
Guidance Raise That Felt Less Than It Looked
The company lifted its full-year 2026 revenue outlook to a range of $890 million to $895 million, from $875 million to $885 million, and raised its adjusted EBITDA margin guidance to 15.5%–16.0%. But roughly $16 million of the increase stemmed from newly consolidated VitalConnect revenue. On an organic basis, the implied fourth-quarter growth of about 10%–12% was flat to slightly below the prior outlook, reinforcing the sense that core momentum had cooled. A GAAP net loss that widened to $29.9 million—driven by litigation settlements tied to the Baxter patent dispute and a securities class action—added to the cautious tone.
Analyst Reactions
Wall Street's response underscored the mixed signals. Needham trimmed its price target to $165 from $194 while keeping a Buy rating, and Piper Sandler lowered its target to $150 from $160 while maintaining Overweight, both citing the Zio AT disruption. Canaccord moved in the opposite direction, lifting its target to $206 from $196 on confidence in the company's strengthening margins. The divergence in revisions reflects the central tension in the story: profitability is improving faster than expected, but near-term growth is being called into question.
Market Context and Trading Activity
The decline occurred on heavy volume as investors re-rated the stock's growth premium, with IRTC breaking decisively below its 20-day and 50-day moving averages and well beneath recent support. The move was largely company-specific rather than a reflection of broader sector weakness, with the medical-technology group trading in a comparatively narrow range on the day. The one-day reset also came after a stretch of relative strength into the report, leaving the stock vulnerable to profit-taking once the growth concerns surfaced.
What Comes Next for IRTC
Investors will be watching whether the Zio AT purchasing pause resolves in early 2027 as VitalConnect's VitalPatch product rolls out through the expanded sales force, and whether the Zio MCT FDA submission proceeds on its revised 2027 schedule. Management has outlined an initial 2027 framework of roughly $1 billion in organic revenue with adjusted EBITDA margins of at least 15%, targets that now serve as the key benchmark against which the integration will be judged. Risks include execution challenges in EHR connectivity and supply-chain scaling, an unresolved FDA warning letter, and the possibility that organic growth continues to decelerate. The next quarterly report, expected in early 2027, will offer the first concrete read on whether the integration is translating into renewed momentum.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers across the market, but only the strongest performers under current conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a data-driven way to scan for opportunities in volatile names like IRTC. Explore the page to see which strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRTC's RSI Indicator slumps oversold zone
The RSI Oscillator for IRTC moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for IRTC crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRTC advanced for three days, in 254 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IRTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 198 of 241 cases where IRTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 66 cases where IRTC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRTC as a result. In 68 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for IRTC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
IRTC moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.990) is normal, around the industry mean (4.142). IRTC has a moderately low P/E Ratio (-214.810) as compared to the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.398) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of monitoring and diagnostic solutions for detection of cardiac arrhythmias
Industry MedicalNursingServices
Advertisement